Last reviewed · How we verify
Intravitreal Methotrexate 400 µg
Intravitreal methotrexate is a chemotherapy agent injected directly into the eye that inhibits dihydrofolate reductase, suppressing DNA synthesis and reducing proliferation of malignant cells in ocular lymphomas.
Intravitreal methotrexate is a chemotherapy agent injected directly into the eye that inhibits dihydrofolate reductase, suppressing DNA synthesis and reducing proliferation of malignant cells in ocular lymphomas. Used for Primary central nervous system lymphoma with vitreous involvement, Intraocular lymphoma.
At a glance
| Generic name | Intravitreal Methotrexate 400 µg |
|---|---|
| Sponsor | JHSPH Center for Clinical Trials |
| Drug class | Antimetabolite; Folate antagonist |
| Target | Dihydrofolate reductase (DHFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Methotrexate is a folate antagonist that blocks dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions and DNA/RNA synthesis. Direct intravitreal administration delivers high local concentrations to the vitreous cavity while minimizing systemic exposure, making it suitable for treating intraocular lymphomas and other vitreous malignancies. The drug's antiproliferative effects target rapidly dividing lymphoid cells.
Approved indications
- Primary central nervous system lymphoma with vitreous involvement
- Intraocular lymphoma
Common side effects
- Cataract
- Retinal toxicity
- Vitreous inflammation
- Corneal epitheliopathy
- Elevated intraocular pressure
Key clinical trials
- A Study in Subjects With Retinitis Pigmentosa (PHASE2)
- Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal Methotrexate 400 µg CI brief — competitive landscape report
- Intravitreal Methotrexate 400 µg updates RSS · CI watch RSS
- JHSPH Center for Clinical Trials portfolio CI